CD2 Monoclonal Antibody (RM2-5), Functional Grade, eBioscience™, Invitrogen™

Descrizione

Description: The RM2-5 monoclonal antibody reacts with the mouse CD2 molecule, an approximately 50-55 kDa cell surface receptor expressed by all mouse lymphocytes. Expression of the CD2 antigen in the mouse differs from that of the human in that B lineage cells in the mouse from the pre-B cell stage to mature B cells express CD2. CD2 is a ligand for CD48 in the mouse and is involved in adhesion and activation of T cells. Applications Reported: The RM2-5 antibody has been reported for use in flow cytometric analysis. RM2-5 has also been reported in in vitro blocking of mouse CD2 (LFA-2). Applications Tested: The RM2-5 antibody has been tested by flow cytometric analysis of mouse splenocytes and bone marrow cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

CD2 (LFA-2) is a monomeric surface antigen (MW range 45-58 kDa) of the human T-lymphocyte lineage that is expressed on all peripheral blood T cells. CD2 is one of the earliest T-cell markers, being present on more than 95% of thymocytes and it is also found on some natural killer cells, but not on B lymphocytes. Monoclonal antibodies directed against CD2 inhibit the formation of rosettes with sheep erythrocytes, indicating that CD2 is the erythrocyte receptor or is closely associated with it. The interaction between CD2 and CD58 stabilizes adhesion between T cells and antigen presenting or target cells. Relatively low affinity of CD2 to CD58 (as measured in solution) is compensated within the two-dimensional cell-cell interface to provide tight adhesion. Moreover, T cell activation induces increased CD2 expression and its lateral mobility, making easier contact between CD2 and CD58. Subsequently, T cell activation causes fixation of CD58-CD2 at sites of cell-cell contact, thereby strengthening intercellular adhesion. CD2 deficiency reduces intestinal inflammation and helps to control infection. Diseases associated with CD2 dysfunction include penis squamous cell carcinoma and immune deficiency due to the absence of the thymus.